2026 Buyer's Guide

Weight Loss Injections (2026): Every FDA-Approved Option

Five FDA-approved injectable medications can produce meaningful weight loss in 2026. Three (Wegovy, Zepbound, Saxenda) are FDA-approved specifically for chronic weight management. Two (Ozempic, Mounjaro) are FDA-approved for type 2 diabetes but commonly prescribed off-label for weight loss. Below: side-by-side comparison, how they work, what they cost, and where to get them.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
9 min read·11 citations

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

Always verify pricing and state availability on the provider's website before signing up.How our reviews work →

About this page

Every drug listed below is FDA-approved with a published label on DailyMed (NIH). Mechanism, indication, administration route, dosing, and approval-date data are pulled from our primary-source-verified drug database. Cost data was verified live on July 2026 from manufacturer self-pay portals (NovoCare, LillyDirect), retailer programs (Costco Member Prescription Program via Sesame, Sam's Club Plus, Amazon Pharmacy), and GoodRx. We do not paraphrase indication language.

What are weight loss injections?

All five FDA-approved weight loss injections currently on the US market are GLP-1 receptor agonists (one is also a GIP/GLP-1 dual agonist). They are self-administered subcutaneous injections — a small needle into the fat layer of the abdomen, thigh, or back of the upper arm — and they reduce appetite via the GLP-1 signaling pathway plus slow gastric emptying. Three are FDA-approved for chronic weight management; two are FDA-approved for type 2 diabetes and prescribed off-label for weight loss when the weight-loss-indicated drugs are unavailable, denied by insurance, or contraindicated. The class history started with Byetta (exenatide) in 2005 for type 2 diabetes; Saxenda was the first weight-management indication in December 2014; Wegovy, Zepbound, and Foundayo followed.

For the deeper biology of GLP-1 — what the hormone is, how the receptor works, and the four physiologic actions (insulin secretion, glucagon suppression, gastric emptying, central appetite suppression) — see our GLP-1 complete guide. For oral weight loss medications (Foundayo, Rybelsus, Qsymia, Contrave, Xenical), see our FDA-approved weight loss medications hub (which compares pills vs injections side-by-side).

Every FDA-approved weight loss injection, compared

All five injections side-by-side. Pivotal trial efficacy cited from the canonical phase 3 publication for each drug; full PMID citations live in our bariatric vs GLP-1 decision guide.

BrandGenericIndicationGuide
WegovySemaglutide 2.4 mgWeight management; CV risk reductionWegovy →
ZepboundTirzepatideWeight management; OSA in obesityZepbound →
SaxendaLiraglutide 3 mgChronic weight managementDailyMed →
OzempicSemaglutide (lower-dose)Type 2 diabetes (off-label for weight loss)Ozempic →
MounjaroTirzepatideType 2 diabetes (off-label for weight loss)Mounjaro →

What weight loss injections cost in 2026

Brand-name injection list prices range widely depending on channel. Verified live 2026-05-09 from manufacturer + retailer primary sources:

Wegovy (semaglutide)

  • NovoCare self-pay: $299/month (standard pen, all doses 0.25–2.4 mg)
  • NovoCare HD pen 7.2 mg: $399/month
  • Wegovy oral pill 1.5/4 mg: $149/month
  • Costco CMPP via Sesame: $349/month (new pt $199 × 2 mo)
  • Sam's Club: $499/month via copay program
  • With insurance copay savings card: as little as $25/month

Zepbound (tirzepatide)

  • LillyDirect vials self-pay (effective Dec 1, 2025): $299 / $399 / $449 by strength
  • LillyDirect KwikPen self-pay: $299–$699 by strength
  • Sam's Club KwikPen: $299/$399/$499/$699
  • GoodRx coupon path: $299/month (manufacturer-funded)

Saxenda (liraglutide)

  • Brand list: ~$1,300/month
  • Generic liraglutide (Teva, launched Aug 28 2025): pricing varies by pharmacy
  • Manufacturer copay savings card: as little as $25/month for commercially insured

Ozempic (off-label) + Mounjaro (off-label)

  • Ozempic NovoCare new patient: $199/mo for first 2 months; $349 standard
  • Ozempic GoodRx: $149/month (oral 1.5 mg) / pen via Novo
  • Mounjaro: no DTC self-pay program; copay savings card for commercial
  • Off-label use is rarely insurance-covered for weight loss when the patient does not have type 2 diabetes

For the live channel-by-channel pricing index across every channel + compounded options ($99–$400/mo), see our GLP-1 pricing index. Brand and compounded GLP-1s are generally HSA/FSA-eligible with a prescription per IRS Publication 502.

How to get a weight loss injection (telehealth, retail, insurance)

Three primary channels:

  • Insurance + traditional prescriber. Your PCP or an obesity-medicine specialist writes the prescription, your pharmacy fills it, your insurance applies the prior-authorization criteria. See our Cigna PA guide and Aetna PA guide for verbatim payer policy. The Cigna 11-condition comorbidity list, the Aetna 6-month behavioral-program requirement, and the CVS Caremark July 2025 Wegovy- preferred swap are the three things most prescribers under-document.
  • GLP-1 telehealth providers. Online clinic + 503A pharmacy partnership. Cash-pay compounded semaglutide / tirzepatide typically $99–$400/ month. See our best semaglutide providers and best tirzepatide providers for ranked options. Note: the FDA's enforcement-discretion grace period for compounded semaglutide ended February 2025 — the regulatory landscape is unsettled.
  • Direct-to-consumer manufacturer pharmacies. NovoCare (Wegovy/Ozempic), LillyDirect (Zepbound/ Mounjaro/Foundayo), Costco CMPP via Sesame partner, Sam's Club Plus, Amazon Pharmacy. Cash-pay only — not eligible for insurance.

Once you have the medication, follow the FDA-label injection technique. See our step-by-step injection technique guide for every common pen and vial format, including the three FDA-approved injection sites (abdomen, thigh, back of upper arm), needle gauge, depth, angle, and the site-rotation schedule that minimizes lipohypertrophy.

Compare vetted GLP-1 telehealth providers

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

No insurance needed · HSA/FSA eligible · vetted by our editors

7.9

Trimi Health

Budget-conscious shoppers

Starting price: $99/mo

Get started →Read review Trimi Health →
7.7

Ro

Broadest GLP-1 formulary including Foundayo on day-one of launch

Starting price: $149/mo

Get started →Read review Ro →
8.0

ShedRx

Mainstream telehealth GLP-1 access

Starting price: $149/mo

Get started →Read review ShedRx →
8.1

bmiMD

Mainstream telehealth GLP-1 access

Starting price: $99/mo

Get started →Read review bmiMD →
7.7

Synergy Rx

Broadest drug catalog in the Lion MD white-label cluster

Starting price: $199/mo

Get started →Read review Synergy Rx →
8.1

RxSpan MD

Physician-led, pharmacy-transparent compounded GLP-1 with brand-name options

Starting price: $179/mo

Get started →Read review RxSpan MD →

Frequently Asked Questions

The strongest published efficacy among FDA-approved weight loss injections is Zepbound (tirzepatide 15 mg) — ~20.9% mean body-weight loss at 72 weeks in SURMOUNT-1 (NEJM 2022). Wegovy (semaglutide 2.4 mg) produces ~14.9% at 68 weeks (STEP-1, NEJM 2021). SURMOUNT-5 (NEJM 2025) confirmed tirzepatide's edge in a head-to-head. Saxenda (liraglutide 3.0 mg) is older and produces ~5-8% at 56 weeks. 'Best' depends on tolerance, insurance coverage, and cost.
Yes — every major US retail pharmacy chain (CVS, Walgreens, Rite Aid, Costco, Sam's Club) dispenses FDA-approved weight loss injections with a valid prescription. Telehealth providers ship nationally. LillyDirect ships Zepbound vials directly via partner pharmacies. NovoCare ships Wegovy. Amazon Pharmacy offers same-day delivery in 3,000+ cities.
FDA-approved weight loss injections have a known published safety profile. Most common adverse reactions are gastrointestinal (nausea, vomiting, diarrhea, constipation, abdominal pain) and peak during dose escalation. Wegovy, Zepbound, and Saxenda all carry a thyroid C-cell tumor boxed warning based on rodent studies; clinical relevance to humans is debated. Documented concerns include gallbladder disease, pancreatitis, ileus, and potential muscle-mass loss with rapid weight loss.
For brand-name FDA-approved injections, Wegovy through NovoCare self-pay at $299/month is the cheapest standard pen as of 2026-05-09. Zepbound vials through LillyDirect run $299-$449/month. Costco Member Prescription Program offers $349/month for Wegovy and Ozempic via the Sesame partner. With insurance and a copay savings card, both Wegovy and Saxenda can be as little as $25/month. Compounded semaglutide / tirzepatide from licensed 503A pharmacies typically run $99-$400/month but are not FDA-approved.
No. Ozempic and Mounjaro are FDA-approved only for type 2 diabetes. Their identical active ingredients are sold under different brand names — Wegovy and Zepbound respectively — for the weight-management indication. Off-label prescribing of Ozempic or Mounjaro for weight loss is legal but typically not insurance-covered.
In 2026 there are two FDA-approved oral GLP-1s (Foundayo, FDA-approved April 2026 for weight management; Rybelsus, for type 2 diabetes only) plus three older non-GLP-1 oral AOMs (Qsymia, Contrave, Xenical/alli). Injectable GLP-1s currently produce larger weight-loss effect sizes in published trials than the oral options, but Foundayo is too new for fair long-term comparison.

References

  1. 1.U.S. Food and Drug Administration / manufacturer label. Wegovy — FDA Prescribing Information (indication, dosing schedule, and boxed-warning language quoted verbatim from the current label). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  2. 2.U.S. Food and Drug Administration / manufacturer label. Zepbound — FDA Prescribing Information (indication, dosing schedule, and boxed-warning language quoted verbatim from the current label). DailyMed, U.S. National Library of Medicine. 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
  3. 3.U.S. Food and Drug Administration / manufacturer label. Ozempic — FDA Prescribing Information (indication, dosing schedule, and boxed-warning language quoted verbatim from the current label). DailyMed, U.S. National Library of Medicine. 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf
  4. 4.U.S. Food and Drug Administration / manufacturer label. Mounjaro — FDA Prescribing Information (indication, dosing schedule, and boxed-warning language quoted verbatim from the current label). DailyMed, U.S. National Library of Medicine. 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
  5. 5.U.S. Food and Drug Administration / Novo Nordisk label. Saxenda (liraglutide 3 mg) — FDA Prescribing Information (dosing ladder, indication, and boxed-warning language quoted verbatim from the current label). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
  6. 6.Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — ~20.9% mean body-weight reduction at 72 weeks (15 mg). New England Journal of Medicine. 2022. PMID: 35658024.
  7. 7.Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — ~14.9% mean body-weight reduction at 68 weeks (2.4 mg). New England Journal of Medicine. 2021. PMID: 33567185.
  8. 8.Garvey WT, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5) — head-to-head superiority of tirzepatide over semaglutide. New England Journal of Medicine. 2025. PMID: 40334173.
  9. 9.Pi-Sunyer X, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes) — ~5-8% mean body-weight reduction at 56 weeks. New England Journal of Medicine. 2015. PMID: 26132939.
  10. 10.Novo Nordisk. NovoCare self-pay pricing for Wegovy and Ozempic — cash-pay pen pricing verified live July 2026. novocare.com. 2026. https://www.novocare.com/
  11. 11.Eli Lilly and Company. LillyDirect self-pay pricing for Zepbound single-dose vials — cash-pay vial pricing by strength verified live July 2026. lilly.com/lillydirect. 2026. https://lillydirect.lilly.com/

Where to go next

GLP-1 complete guide →
What GLP-1 actually is, how the receptor agonist drug class works, and every FDA-approved GLP-1 medication including the diabetes-only and discontinued legacy drugs.
FDA-approved weight loss medications hub →
Master overview of every weight-loss-indicated drug — injections, oral pills, pipeline, and non-GLP-1 anti-obesity medications.
Best semaglutide providers →
Ranked telehealth + retail pharmacy options for Wegovy, Ozempic, and compounded semaglutide.
Best tirzepatide providers →
Ranked telehealth + retail pharmacy options for Zepbound, Mounjaro, and compounded tirzepatide.
How to inject GLP-1 — step-by-step →
FDA-label-cited injection technique for every pen and vial format. Three injection sites, needle gauge, depth, rotation schedule.
Live GLP-1 pricing index →
Channel-by-channel cash and insured pricing across NovoCare, LillyDirect, Costco, Sam's Club, Amazon Pharmacy, GoodRx, and compounded options.